LEXINGTON, Mass., July 12, 2016 /PRNewswire/
-- scPharmaceuticals, Inc., a privately held biopharmaceutical
company developing transformative pharmaceutical products for
subcutaneous delivery, announced today that Jack A. Khattar has been appointed to
scPharmaceuticals' board of directors.
Jack A. Khattar is the founder of
Supernus Pharmaceuticals (NASDAQ: SUPN) and has served as president
and Chief Executive Officer and Director since 2005. From 1999 to
2005, Mr. Khattar served in various positions, including Board
Member, president and CEO of Shire Laboratories Inc., the drug
delivery subsidiary of Shire plc. Prior to that, Mr. Khattar served
as an Executive Officer and the Chairman of the Management
Committee at CIMA, a drug delivery company where he was also
responsible for business development, corporate alliances and
strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held
several marketing and business development positions at Merck &
Co., Novartis, Playtex, and Kodak in various locations, including
the United States, Europe and the Middle East. He served as a director of
Rockville Economic Development Inc. from 2003 until 2013. He
currently serves on the Board of Directors of Prevacus, Inc., a
privately-held pharmaceutical company. Mr. Khattar earned his
degrees in marketing, with a BBA from American
University of Beirut and an MBA from the Wharton School of
the University of Pennsylvania.
"At this time of transition from a development to a commercial
focus at scPharmaceuticals, it is a privilege to have Jack Khattar join the board of directors," said
Pieter Muntendam, president, CEO and
founder of scPharmaceuticals and a member of its board of
directors. "Mr. Khattar is a successful CEO of a public
pharmaceutical company and brings to the board broad and extensive
commercial experience combined with a thorough understanding of all
aspects of a pharmaceutical enterprise."
"Using innovative delivery technology, scPharmaceuticals aims to
reduce healthcare costs while improving patient care," said Mr.
Khattar. "The need to reduce cost of care while improving outcomes
has never been greater and I look forward to working with
scPharmaceuticals to advance the company and address an important
societal need."
About scPharmaceuticals:
scPharmaceuticals, based in Lexington,
MA, is a privately held biopharmaceutical company developing
a portfolio of transformative pharmaceutical products for
subcutaneous delivery. Based on widely used generic drugs
that currently require intravenous or intramuscular injections,
innovative products will be administered subcutaneously via a
proprietary patch pump. This avoids material risks and costs
associated with the current delivery options. Our lead
products are the first subcutaneous formulations of furosemide (the
most widely used parenteral diuretic in treating heart failure) and
ceftriaxone (the most widely used parenteral antibiotic outside the
hospital setting). Our novel furosemide formulation
enables convenient anytime anywhere use, for example in an
outpatient setting instead of the emergency room or other
in-patient settings. For ceftriaxone and other antibiotics,
subcutaneous administration eliminates the need for PICCs
(peripherally inserted central catheters), which are associated
with serious complications, frequent adverse events and high
medical cost. For further information on how we are
transforming the administration of parenteral drugs, go to
www.scpharmaceuticals.com.
Logo - http://photos.prnewswire.com/prnh/20150417/199710LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/supernus-pharmaceuticals-founder-and-ceo-jack-khattar-joins-scpharmaceuticals-board-of-directors-300296736.html
SOURCE scPharmaceuticals, Inc.